-
-
Whenever there is a pullback, investors watch the market closely in order to try and time their entry into stocks they are following hoping to pick them up at favourable prices. However, when they actually .
< Back to Blog
My Blog Posts
-
-
What is the impact of tariff hikes?
Full Story | Kristian Camenzuli - Investment Manager | 20th May 2019Even though the latest tariff hike (from 10% to 25% on $200bn of Chinese imports) is likely to have a modest direct impact on Chinese and US GDP (-0.2%), neither side has any interest in .
-
-
BMW Shares – Tough Times Ahead
Full Story | Kristian Camenzuli - Investment Manager | 25th March 2019We downgraded our stance on BMW from a Buy to a Hold and reduced our price target from €94 to €75.60. The 2018 results were disappointing but persistent headwinds in 2019 are making the valuation .
-
-
China’s importance in global equity valuations
Full Story | Kristian Camenzuli - Investment Manager | 25th March 2019The developed world needs to come to terms with the fact that China is the world’s second largest economy and in some ways soon to become the leading economic force globally. Today China matters more .
-
-
AXA – A new addition to our equity list
Full Story | Kristian Camenzuli - Investment Manager | 20th March 2019We commence coverage on AXA with a Buy rating and a 12-month price target of €27. 2018 was a turning point for the Group in which we saw a corporate restructuring which we believe will .
-
-
An outlook for equity and bond markets in 2019
Full Story | Kristian Camenzuli - Investment Manager | 11th February 2019In 2018, investors experienced volatile markets. Nonetheless, markets started 2019 in rally mode within a macro-economic and political context of significant issues such as Brexit and the China-US trade war. Investors are now asking which .
-
-
Sanofi – Investing in healthcare
Full Story | Kristian Camenzuli - Investment Manager | 11th February 2019Sanofi reported positive results for Q418 beating on revenue and earnings when compared to our estimates and consensus. Revenues last year were led higher by Sanofi’s Genzyme biotechnology unit, were growth was up 37.4 per .
-
-
Attractive High Dividend Paying Stocks in Europe
Full Story | Kristian Camenzuli - Investment Manager | 3rd December 2018Investing in companies with attractive dividend payouts, also known as a form of income investing, aims to pick companies that provide a constant and reliable stream of income in the form of dividend payments. It .
-
-
Renault – Are the shares still a buy?
Full Story | Kristian Camenzuli - Investment Manager | 26th November 2018Shares of Renault came under pressure last week after the arrest of Carlos Ghosn for serious misconduct including systematic understatement of his Nissan compensation and misuse of company assets.Who is Carlos Ghosn?Carlos Ghosn is the .
-
-
Allianz – A stock that continues to deliver
Full Story | Kristian Camenzuli - Investment Manager | 12th November 2018Following Allianz’s Q3 2018 results, we maintain our BUY recommendation on the stock and Price Target of €207.We like Allianz for the following reasons:- Very well capitalised- Buybacks- Strong management provides confidence- Indicative Gross Dividend .
